Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update End-of-treatment data from two Phase 2a combination clinical trials with imdusiran to be presented at the EASL Congress in June 2024 Preliminary data from the single-dose portion of the AB-101-001...

Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update WARMINSTER, Pa., April 18, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a...

Texas Capital Bancshares, Inc. Announces First Quarter 2024 Results First quarter 2024 net income of $26.1 million and net income available to common stockholders of $21.8 million, or $0.46 per diluted share First quarter 2024 growth in loans held for...

Texas Capital Bancshares, Inc. Announces Date for Q1 2024 Operating Results DALLAS, April 04, 2024 (GLOBE NEWSWIRE) -- Texas Capital Bancshares, Inc. (NASDAQ: TCBI), the parent company of Texas Capital Bank, today announced that it expects to issue financial results for the...